News

Agios Pharmaceuticals Highlights Third Quarter Progress and Results

Agios Pharmaceuticals Highlights Third Quarter Progress and Results

Agios Pharmaceuticals Reports Financial Results for Q3 2025

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has announced its third-quarter financial results, reflecting a continued commitment to delivering innovative treatments in rare diseases. The significant milestones achieved during this period highlight the potential of its flagship product, PYRUKYND (mitapivat), in addressing challenging medical needs.

Key Financial Highlights

For the third quarter of 2025, Agios reported net revenues amounting to $12.9 million from PYRUKYND. This marks an impressive 44% increase from the $9.0 million reported during the same period last year. Compared to the second quarter of 2025, where revenues were at $12.5 million, this 3% growth illustrates the company’s ongoing upward trajectory.

Patient Enrollment and Therapy Initiations

Agios has observed promising trends in patient engagement. The enrollment forms submitted by unique patients surpassed 262, demonstrating a 6% increase over the previous quarter. Of these, 149 patients are currently receiving therapy in the U.S., indicating a supportive environment for the adoption of PYRUKYND among healthcare professionals.

Regulatory Updates and Clinical Trials

The company is poised for important regulatory milestones related to PYRUKYND. The U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) goal date of December 7, 2025, for the supplemental New Drug Application (sNDA) specifically addressing treatment for thalassemia patients. This extension was a response to the FDA's request for a Risk Evaluation and Mitigation Strategy (REMS), ensuring a thorough review process. Importantly, no new efficacy or safety data was requested, confirming the strength of previous submissions.

International Regulatory Advancements

In addition to U.S. progress, Agios has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending approval of PYRUKYND for the treatment of anemia linked to both transfusion-dependent and non-transfusion-dependent thalassemia in adults. A final ruling from the European Commission is anticipated early in 2026.

Upcoming Trials and Strategic Initiatives

The RISE UP Phase 3 trial, focusing on the efficacy of mitapivat in sickle cell disease, is expected to release its topline results by the end of this year, with a potential U.S. commercial launch slated for 2026. Moreover, the enrollment for the Phase 2b tebapivat trial in lower-risk Myelodysplastic Syndromes (MDS) has been completed, with topline results expected in early 2026.

Financial Overview

As of September 30, 2025, Agios reported substantial liquidity with cash, cash equivalents, and marketable securities reaching $1.3 billion. This financial cushion is vital as the company prepares for upcoming commercial launches and continues to invest in its innovative pipeline aimed at rare diseases.

Management Insights and Commitment to Patients

Brian Goff, CEO of Agios, emphasized the company’s dedication to addressing the urgent needs within rare disease communities. 'We remain focused on our two key PYRUKYND milestones and the urgent need for innovation in the treatment of these serious diseases. Our commitment does not waver as we look to provide meaningful progress for patients in need.'

Frequently Asked Questions

What financial results did Agios Pharmaceuticals announce for Q3 2025?

Agios reported net revenues of $12.9 million for Q3 2025, a significant increase from previous quarters.

What are the upcoming regulatory milestones for PYRUKYND?

The FDA has set a PDUFA goal date of December 7, 2025, for PYRUKYND’s supplementary application for thalassemia treatment.

How has patient enrollment changed for PYRUKYND?

There was a 6% increase in unique patients completing prescription enrollment forms, totaling 262 in Q3 2025.

What are the upcoming clinical results expected from Agios?

Topline results from the RISE UP Phase 3 trial in sickle cell disease are anticipated by year-end 2025.

How does Agios plan to utilize its cash reserves?

Agios aims to use its $1.3 billion in cash for potential commercial launches and advancing its clinical programs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 112

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 140

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 109

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 100

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 111

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading

Top 5 Most Recently Viewed Articles

SiriusPoint Declares Cash Dividend on Series B Preference Shares

Updated Category News Views 123

SiriusPoint Declares Quarterly Cash Dividend for Investors In a significant move for its shareholders, SiriusPoint Ltd. has recently revealed the approval of a quarterly cash dividend of $0.50 per share for the 8.00% Resettable Fixed Rate Preference Shares, Series B. This decision, endorsed by the Audit Committee of the Board of Directors, showcases the company's...

Continue Reading
Urban One Welcomes New Leadership as CEO David Kantor Retires

Updated Category News Views 435

Changes in Leadership at Urban One Urban One has made a significant announcement regarding changes at the helm of its audio division. Currently, the company bids farewell to CEO David Kantor, a well-respected figure in the industry, whose tenure has shaped Urban One into a key player in audio entertainment. Kantor's retirement, set for early 2025, opens the door for new...

Continue Reading
Mattamy Homes Expands Presence with New Division in Florida

Updated Category News Views 502

Mattamy Homes Expands Operations in Florida Company strengthens regional focus to enhance customer service, empower teams and drive future expansion Mattamy Homes US has officially launched a new division centered in Southwest Florida. This strategic initiative is set to improve operational agility, allowing Mattamy to provide exceptional service to its customers...

Continue Reading
Eloro Resources Secures $3.78 Million in Latest Placement

Updated Category News Views 235

Eloro Resources Completes Private Placement Successfully Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) has announced a significant achievement in its funding efforts. The company successfully closed its non-brokered private placement offering, concluding with a total of 4,200,000 units sold. This move resulted in gross proceeds of approximately $3,780,000,...

Continue Reading
Groundbreaking Global Health Exhibition Set to Transform Healthcare

Updated Category News Views 54

Global Health Exhibition Promises Unmatched Innovation Tomorrow marks the opening of the much-anticipated Global Health Exhibition, an international healthcare event attracting over 100,000 professionals dedicated to health and patient care. Spanning across three days, this premier event will host an impressive assembly of over 1,200 exhibiting companies and brands,...

Continue Reading